TGFB1 and neoplasm: Using mouse models that recapitulate the immune-excluded phenotype they further show that co-administration of blocking antibodies to TGFβ and PDL1 reduced TGFβ signaling, facilitated T-cell penetration of tumors, and provoked vigorous anti-tumor immunity leading to tumor regressions.